Carfilzomib,Daratumumab,Dexamethasone,Lenalidomide
Janssen
['mmsm']
congress | #eha2023 | jes s san miguel, presents on the benefits and controversies of using mrd as an endpoint in clinical trials. he suggests mrd may be used to evaluate therapy efficacy and to make clinical decisions such as introducing early rescue intervention. #mmsm 
The Multiple Myeloma (MM) Hub is an online educational resource run in collaboration with the European School of Haematology @ESHaematology #mmsm #myeloma